|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 February 2002, Vol. 99, No. 4, pp. 1165-1173
GENE THERAPY
Retrovirus-mediated gene transfer in primary T lymphocytes
impairs their anti-Epstein-Barr virus potential through both
culture-dependent and selection process-dependent
mechanisms
Delphine Sauce,
Marie Bodinier,
Marina Garin,
Bruno Petracca,
Nicolas Tonnelier,
Anne Duperrier,
Junia V. Melo,
Jane F. Apperley,
Christophe Ferrand,
Patrick Hervé,
François Lang,
Pierre Tiberghien, and
Eric Robinet
From INSERM E-0119/UPRES EA-2284, Etablissement
Français du Sang- Bourgogne/Franche-Comté, Besançon,
France; INSERM U463, Institut de Biologie, Nantes, France; and
Haematology Department, Hammersmith Hospital, London, United Kingdom.
To modulate alloreactivity after hematopoietic stem cell
transplantation, suicide gene-expressing donor T cells can be
administered with an allogeneic T-cell-depleted bone marrow graft.
Immune competence of such cells is a critical issue. The impact
of the ex vivo gene transfer protocol (12-day culture period including
CD3/interleukin-2 [IL-2] activation, retroviral-mediated gene
transfer, and G418-based selection) on the anti-Epstein-Barr virus
(EBV) potential of gene-modified cells has been examined. Cytotoxic
(pCTL) and helper (pTh) cell precursor limiting dilution
assays, interferon- enzyme-linked immunospot, or
fluorescence-activated cell sorter analysis after tetrameric HLA-A2/EBV
peptide complexes revealed that the frequency of anti-EBV T cells was
lower in gene-modified cells (GMCs) than in similarly cultured but
untransduced T cells and was even lower than in fresh peripheral blood
mononuclear cells, demonstrating both an effect of the culture and of
the transduction or selection. The culture-dependent loss of
EBV-reactive cells resulted from the preferential induction of
activation-induced cell death in tetramer+ cells. Replacing
the initial CD3/IL-2 activation by CD3/CD28/IL-2 partially restored the
anti-EBV response of GMCs by reducing the initial activation-induced
cell death and enhancing the proliferation of EBV-tetramer+
cells. Moreover, the G418 selection, and not the transduction, was
directly toxic to transduced tetramer+ cells. Replacing the
G418 selection by an immunomagnetic selection significantly prevented
the selection-dependent loss of EBV-specific cells. Overall, ex vivo
gene modification of primary T cells can result in a significant
reduction in EBV-reactive T cells through both culture-dependent and
selection-dependent mechanisms. Improving immune functions of GMCs
through modifications of the cell culture conditions and
transduction/selection processes is critical for further clinical studies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Kaneko, S. Mastaglio, A. Bondanza, M. Ponzoni, F. Sanvito, L. Aldrighetti, M. Radrizzani, S. La Seta-Catamancio, E. Provasi, A. Mondino, et al.
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes
Blood,
January 29, 2009;
113(5):
1006 - 1015.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Selmani, A. Naji, I. Zidi, B. Favier, E. Gaiffe, L. Obert, C. Borg, P. Saas, P. Tiberghien, N. Rouas-Freiss, et al.
Human Leukocyte Antigen-G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells
Stem Cells,
January 1, 2008;
26(1):
212 - 222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Hombach, D. Kofler, A. Hombach, G. Rappl, and H. Abken
Effective Proliferation of Human Regulatory T Cells Requires a Strong Costimulatory CD28 Signal That Cannot Be Substituted by IL-2
J. Immunol.,
December 1, 2007;
179(11):
7924 - 7931.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Deschamps, P. Mercier-Lethondal, J. M. Certoux, C. Henry, B. Lioure, C. Pagneux, J. Y. Cahn, E. Deconinck, E. Robinet, P. Tiberghien, et al.
Deletions within the HSV-tk transgene in long-lasting circulating gene-modified T cells infused with a hematopoietic graft
Blood,
December 1, 2007;
110(12):
3842 - 3852.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Tiberghien
Altruistic donor T cells
Blood,
June 1, 2007;
109(11):
4595 - 4595.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Ciceri, C. Bonini, S. Marktel, E. Zappone, P. Servida, M. Bernardi, A. Pescarollo, A. Bondanza, J. Peccatori, S. Rossini, et al.
Antitumor effects of HSV-TK engineered donor lymphocytes after allogeneic stem-cell transplantation
Blood,
June 1, 2007;
109(11):
4698 - 4707.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Amrolia, G. Muccioli-Casadei, H. Huls, S. Adams, A. Durett, A. Gee, E. Yvon, H. Weiss, M. Cobbold, H. B. Gaspar, et al.
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
Blood,
September 15, 2006;
108(6):
1797 - 1808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Berger, M. E. Flowers, E. H. Warren, and S. R. Riddell
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation
Blood,
March 15, 2006;
107(6):
2294 - 2302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bondanza, V. Valtolina, Z. Magnani, M. Ponzoni, K. Fleischhauer, M. Bonyhadi, C. Traversari, F. Sanvito, S. Toma, M. Radrizzani, et al.
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes
Blood,
March 1, 2006;
107(5):
1828 - 1836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mesel-Lemoine, M. Cherai, S. Le Gouvello, M. Guillot, V. Leclercq, D. Klatzmann, V. Thomas-Vaslin, and F. M. Lemoine
Initial depletion of regulatory T cells: the missing solution to preserve the immune functions of T lymphocytes designed for cell therapy
Blood,
January 1, 2006;
107(1):
381 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Cohen, Z. Zheng, R. Bray, Y. Zhao, L. A. Sherman, S. A. Rosenberg, and R. A. Morgan
Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR
J. Immunol.,
November 1, 2005;
175(9):
5799 - 5808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bonyhadi, M. Frohlich, A. Rasmussen, C. Ferrand, L. Grosmaire, E. Robinet, J. Leis, R. T. Maziarz, P. Tiberghien, and R. J. Berenson
In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia
J. Immunol.,
February 15, 2005;
174(4):
2366 - 2375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Rettig, J. K. Ritchey, J. L. Prior, J. S. Haug, D. Piwnica-Worms, and J. F. DiPersio
Kinetics of In Vivo Elimination of Suicide Gene-Expressing T Cells Affects Engraftment, Graft-versus-Host Disease, and Graft-versus-Leukemia after Allogeneic Bone Marrow Transplantation
J. Immunol.,
September 15, 2004;
173(6):
3620 - 3630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel
Graft-versus-leukemia reactions in allogeneic chimeras
Blood,
February 1, 2004;
103(3):
767 - 776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Sauce, N. Rufer, P. Mercier, M. Bodinier, J.-P. Remy-Martin, A. Duperrier, C. Ferrand, P. Herve, P. Romero, F. Lang, et al.
Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells
Blood,
August 15, 2003;
102(4):
1241 - 1248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cavalieri, S. Cazzaniga, M. Geuna, Z. Magnani, C. Bordignon, L. Naldini, and C. Bonini
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence
Blood,
July 15, 2003;
102(2):
497 - 505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle
Side effects of retroviral gene transfer into hematopoietic stem cells
Blood,
March 15, 2003;
101(6):
2099 - 2113.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Marktel, Z. Magnani, F. Ciceri, S. Cazzaniga, S. R. Riddell, C. Traversari, C. Bordignon, and C. Bonini
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation
Blood,
February 15, 2003;
101(4):
1290 - 1298.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C.M. Straathof, C. M. Bollard, C. M. Rooney, and H. E. Heslop
Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children
Oncologist,
February 1, 2003;
8(1):
83 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Berger, C. A. Blau, T. Clackson, S. R. Riddell, and S. Heimfeld
CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy
Blood,
January 15, 2003;
101(2):
476 - 484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. E. Heslop, F. K. Stevenson, and J. J. Molldrem
Immunotherapy of Hematologic Malignancy
Hematology,
January 1, 2003;
2003(1):
331 - 349.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|